Amarin Corp Plc price to sales ratio AMRN

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: 1.3×
10-year median: 2.7×
Against its 10-year history: 25th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.7× to 33.8×
Peer median: 1.4×

Amarin Corp Plc's price to sales ratio is 1.3× as of Oct 23, 2026.

That is below its ten-year median of 2.7×, lower than on 75% of days in the last ten years.

Over that time it ranged from 0.7× in Apr 2025 to 33.8× in Nov 2018.

The median for 10 large drugmakers of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.3×	1.3×	1.6×
2025	1.3×	0.7×	1.9×
2024	0.8×	0.8×	1.7×
2023	1.1×	0.8×	2.1×
2022	1.2×	0.9×	2.4×
2021	2.2×	2.2×	5.5×
2020	3.2×	2.7×	20.7×
2019	21.3×	16.7×	32.1×
2018	19.6×	4.0×	33.8×
2017	6.5×	5.2×	8.2×
2016	7.0×	6.4×	7.8×

Against its peers

Companies in Drug Manufacturers - General nearest Amarin Corp Plc's size, closest first, today.

Company	Price to sales ratio
AMRNAmarin Corp Plc	1.3×
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
ABUSArbutus Biopharma	4.6×
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
Peer median	1.4×

Where Amarin Corp Plc ranks

#27of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Amarin Corp Plc

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.